Chemotherapy plays an important role in the management of patients with locally advanced and metastatic transitional cell carcinoma of the urothelial tract. Chemotherapeutic regimens have evolved from use of single drugs with low response rates and a short median survival to combination chemotherapy with inclusion of new active drugs which achieve response rates up to 75–80% and the possibility of cure in about 15% of patients with good performance status and without visceral metastases. Patients with a primary good response are candidates for subsequent surgery or radiotherapy of residual disease.
American Journal of Cancer – Springer Journals
Published: Dec 31, 2005
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.